OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $252.27 million. The enterprise value is $268.50 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.50 million shares outstanding. The number of shares has increased by 5.60% in one year.
| Current Share Class | 18.50M |
| Shares Outstanding | 18.50M |
| Shares Change (YoY) | +5.60% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 14.50% |
| Owned by Institutions (%) | 60.44% |
| Float | 14.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 25.60 |
| PS Ratio | 2.55 |
| Forward PS | 2.36 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 281.87 |
| P/FCF Ratio | 38.64 |
| P/OCF Ratio | 38.02 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 262.46, with an EV/FCF ratio of 41.13.
| EV / Earnings | n/a |
| EV / Sales | 2.85 |
| EV / EBITDA | 262.46 |
| EV / EBIT | n/a |
| EV / FCF | 41.13 |
Financial Position
The company has a current ratio of 2.82, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.82 |
| Quick Ratio | 2.69 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 25.79 |
| Debt / FCF | 5.02 |
| Interest Coverage | -0.56 |
Financial Efficiency
Return on equity (ROE) is -12.91% and return on invested capital (ROIC) is -1.34%.
| Return on Equity (ROE) | -12.91% |
| Return on Assets (ROA) | -1.20% |
| Return on Invested Capital (ROIC) | -1.34% |
| Return on Capital Employed (ROCE) | -2.21% |
| Revenue Per Employee | $731,512 |
| Profits Per Employee | -$119,457 |
| Employee Count | 129 |
| Asset Turnover | 0.55 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -704,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.81% in the last 52 weeks. The beta is 1.33, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | +32.81% |
| 50-Day Moving Average | 11.52 |
| 200-Day Moving Average | 7.52 |
| Relative Strength Index (RSI) | 56.80 |
| Average Volume (20 Days) | 344,737 |
Short Selling Information
The latest short interest is 1.57 million, so 8.49% of the outstanding shares have been sold short.
| Short Interest | 1.57M |
| Short Previous Month | 1.54M |
| Short % of Shares Out | 8.49% |
| Short % of Float | 11.02% |
| Short Ratio (days to cover) | 3.83 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $94.37 million and -$15.41 million in losses. Loss per share was -$0.84.
| Revenue | 94.37M |
| Gross Profit | 60.52M |
| Operating Income | -3.30M |
| Pretax Income | -25.32M |
| Net Income | -15.41M |
| EBITDA | 1.02M |
| EBIT | -3.30M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $16.57 million in cash and $32.80 million in debt, giving a net cash position of -$16.23 million or -$0.88 per share.
| Cash & Cash Equivalents | 16.57M |
| Total Debt | 32.80M |
| Net Cash | -16.23M |
| Net Cash Per Share | -$0.88 |
| Equity (Book Value) | 116.27M |
| Book Value Per Share | 6.29 |
| Working Capital | 33.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.64 million and capital expenditures -$107,000, giving a free cash flow of $6.53 million.
| Operating Cash Flow | 6.64M |
| Capital Expenditures | -107,000 |
| Free Cash Flow | 6.53M |
| FCF Per Share | $0.35 |
Full Cash Flow StatementMargins
Gross margin is 64.13%, with operating and profit margins of -3.50% and -16.33%.
| Gross Margin | 64.13% |
| Operating Margin | -3.50% |
| Pretax Margin | -17.08% |
| Profit Margin | -16.33% |
| EBITDA Margin | 1.08% |
| EBIT Margin | -3.50% |
| FCF Margin | 6.92% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.60% |
| Shareholder Yield | -5.60% |
| Earnings Yield | -6.11% |
| FCF Yield | 2.59% |
Analyst Forecast
The average price target for OptimizeRx is $10.81, which is -20.75% lower than the current price. The consensus rating is "Buy".
| Price Target | $10.81 |
| Price Target Difference | -20.75% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 0.33333:1.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.33333:1 |
Scores
OptimizeRx has an Altman Z-Score of 1.7 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.7 |
| Piotroski F-Score | 5 |